Details of the Drug Formulations

General Information of Drug (ID: DMGM2Z6)

Drug Name
Lonafarnib Drug Info
Synonyms
Sarasar; Lonafarnib [USAN]; Sch 66336; Sch66336; SCH-066336; Sch-66336; Lonafarnib (USAN/INN); (+)-4-(2-(4-(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-piperidin-1-yl))-2-oxoethyl)-piperidine-1-carboxamide; (+)-4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-1-piperidinecarboxamide; (+)-4[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6] cyclohepta[1,2-b]-pyridin-11(R)-yl-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide; 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-1-piperidinecarboxamide; 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide; 4-{2-[4-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDIN-11-YL)PIPERIDIN-1-YL]-2-OXOETHYL}PIPERIDINE-1-CARBOXAMIDE
Indication
Disease Entry ICD 11 Status REF
Hutchinson-Gilford progeria syndrome LD2B Approved [1]
Myelodysplastic syndrome 2A37 Phase 3 [2]
Hepatitis D virus infection 1E51.2 Phase 2 [3]
Non-small-cell lung cancer 2C25.Y Discontinued in Phase 3 [4]
Therapeutic Class
Anticancer Agents
Cross-matching ID
PubChem CID
148195
ChEBI ID
CHEBI:47097
CAS Number
193275-84-2
TTD ID
D0W4HZ
INTEDE ID
DR1861
ACDINA ID
D01220

Full List of Drug Formulations Containing This Drug

Lonafarnib 50 mg capsule
Company Formulation ID FDA Description
Eiger Biopharmaceuticals F24392 Croscarmellose Sodium; Magnesium Stearate; Poloxamer 188; Povidone; Silicon Dioxide; Gelatin; Titanium Dioxide; Yellow Iron Oxide; Red Iron Oxide; Ammonia Solution; Black Iron Oxide; Butyl Alcohol; Dehydrated Alcohol; Isopropyl Alcohol; Potassium Hydroxide; Propylene Glycol; Purified Water; Shellac
------------------------------------------------------------------------------------
Lonafarnib 75 mg capsule
Company Formulation ID FDA Description
Eiger Biopharmaceuticals F24418 Croscarmellose Sodium; Magnesium Stearate; Poloxamer 188; Povidone; Silicon Dioxide; Gelatin; Titanium Dioxide; Yellow Iron Oxide; Red Iron Oxide; Ammonia Solution; Black Iron Oxide; Butyl Alcohol; Dehydrated Alcohol; Isopropyl Alcohol; Potassium Hydroxide; Propylene Glycol; Purified Water; Shellac
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2 ClinicalTrials.gov (NCT00109538) Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8024).